| Quarterly Financials | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 283 | 273 | 265 | 314 | 292 | 316 | 291 | 299 | 258 | 319 | 336 | 332 | 375 | 348 | 380 | 464 | 406 | 478 | 474 | 459 | 546 | 578 | 533 | 503 | 582 | 580 | 642 | 697 | 622 | 688 | 665 | 743 | 662 | 642 | 608 | 621 | 557 | 600 | 569 | 679 | 591 |
| Expenses | 240 | 230 | 226 | 269 | 244 | 265 | 247 | 253 | 223 | 267 | 282 | 274 | 322 | 300 | 328 | 403 | 351 | 409 | 410 | 378 | 411 | 462 | 425 | 421 | 500 | 506 | 545 | 608 | 555 | 614 | 593 | 649 | 577 | 565 | 536 | 534 | 490 | 531 | 495 | 583 | 516 |
| EBITDA | 44 | 42 | 40 | 45 | 48 | 51 | 43 | 46 | 36 | 53 | 54 | 57 | 54 | 47 | 52 | 61 | 55 | 69 | 64 | 81 | 135 | 117 | 108 | 82 | 81 | 74 | 97 | 89 | 67 | 74 | 72 | 94 | 85 | 77 | 72 | 87 | 66 | 69 | 74 | 95 | 74 |
| Operating Profit % | 15 % | 16 % | 15 % | 14 % | 16 % | 16 % | 15 % | 16 % | 14 % | 16 % | 16 % | 17 % | 14 % | 14 % | 14 % | 12 % | 13 % | 14 % | 13 % | 16 % | 25 % | 20 % | 20 % | 16 % | 14 % | 13 % | 14 % | 12 % | 11 % | 11 % | 11 % | 13 % | 13 % | 12 % | 12 % | 14 % | 12 % | 11 % | 11 % | 14 % | 13 % |
| Depreciation | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 11 | 11 | 12 | 12 | 12 | 13 | 12 | 13 | 13 | 12 | 12 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 14 | 13 | 14 | 14 | 15 | 15 |
| Interest | 10 | 11 | 11 | 12 | 10 | 9 | 9 | 9 | 9 | 8 | 9 | 9 | 9 | 10 | 11 | 10 | 9 | 9 | 8 | 8 | 7 | 7 | 5 | 4 | 4 | 5 | 5 | 6 | 7 | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 |
| Profit Before Tax | 25 | 23 | 23 | 25 | 29 | 33 | 24 | 31 | 17 | 35 | 35 | 38 | 34 | 27 | 31 | 40 | 34 | 48 | 43 | 61 | 116 | 97 | 90 | 65 | 65 | 56 | 79 | 71 | 48 | 53 | 50 | 73 | 64 | 56 | 52 | 64 | 44 | 46 | 51 | 71 | 51 |
| Tax | 8 | 7 | 6 | 6 | 9 | 11 | 6 | 9 | 5 | 11 | 12 | 14 | 10 | 9 | 10 | 12 | 11 | 16 | 15 | 2 | 31 | 22 | 22 | 14 | 16 | 14 | 20 | 15 | 13 | 14 | 13 | 17 | 16 | 17 | 15 | 17 | 11 | 11 | 14 | 8 | -3 |
| Net Profit | 17 | 16 | 17 | 19 | 20 | 22 | 18 | 22 | 11 | 24 | 23 | 24 | 23 | 18 | 21 | 27 | 23 | 32 | 28 | 59 | 85 | 75 | 68 | 52 | 49 | 43 | 58 | 55 | 35 | 39 | 37 | 56 | 48 | 40 | 37 | 47 | 33 | 35 | 37 | 63 | 54 |
| EPS in ₹ | 7.18 | 6.49 | 7.03 | 7.68 | 8.21 | 9.11 | 7.56 | 8.70 | 4.77 | 9.89 | 9.78 | 9.97 | 9.82 | 7.65 | 8.86 | 12.06 | 9.56 | 13.87 | 11.92 | 25.26 | 9.17 | 8.08 | 7.30 | 5.54 | 5.25 | 4.60 | 6.29 | 5.97 | 3.76 | 4.18 | 3.96 | 6.07 | 5.18 | 4.29 | 3.99 | 5.15 | 3.62 | 3.83 | 4.06 | 6.88 | 5.91 |
Aarti Drugs
Aarti Drugs
527.60
-10.15
(-1.89%)
Market Cap
4,815.40 Cr
EPS
18.35
PE Ratio
25.67
Dividend Yield
0.19 %
Industry
Healthcare52 Week High
635.00
52 Week Low
312.00
PB Ratio
3.54
Debt to Equity
0.47
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from1 analysts
Company News
View All News
Aarti Drugs Limited reported quarterly revenue growth of 6% year-on-year to INR591 crores, driven by a 5% growth in API business volumes. The company achieved gross profit margin improvement of 130 basis points to 36.8% and EBITDA growth of 12% to INR74 crores with margins at 12.6%. The improvement was attributed to normalization of input costs. The company's greenfield project at Sayakha Gujarat has started trial production for anti-diabetic products backward integration. The Tarapur facility for salicylic acid production faced initial startup issues but is expected to contribute from Q3 FY26, with current output below 200 tonnes per month targeting 800 tonnes soon. Formulation business grew 14% to INR80 crores with 57% from exports. The company received USFDA approval for its oncology facility and UK MHRA approval for oral solid dosage facility. Management expects capex of INR150-200 crores for FY26 and targets 15% CAGR volume growth over FY26-27. Net debt stands at INR597 crores with debt-to-equity ratio of 0.42-0.43.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,702.20 | #1 4,08,414.80 | 35.66 | #1 54,729.00 | 12.06 | #1 10,980 | -18.99 | 55.97 | |
6,584.00 | 1,74,784.50 | 79.73 | 9,712.00 | 0.89 | 2,191 | 23.05 | 40.37 | |
1,572.00 | 1,26,971.70 | 23.53 | 28,409.50 | 7.12 | 5,291 | 9.88 | 70.77 | |
3,622.90 | 1,22,615.40 | 60.75 | 11,539.40 | 6.99 | 1,911 | 19.91 | 72.46 | |
1,287.40 | 1,07,442.70 | #1 18.90 | 33,741.20 | 16.73 | 5,725 | 1.26 | 54.50 | |
2,541.60 | 1,04,899.10 | 60.41 | 12,744.20 | 19.57 | 2,007 | -10.91 | 52.39 | |
980.10 | 98,621.00 | 21.20 | 23,511.00 | 13.82 | 4,615 | -0.19 | 54.96 | |
1,960.50 | 89,535.10 | 27.57 | 22,909.50 | #1 19.94 | 3,306 | #1 112.49 | 53.75 | |
32,895.00 | 69,899.60 | 49.39 | 6,684.70 | 10.80 | 1,414 | 27.83 | 42.22 | |
1,127.00 | 65,456.30 | 18.95 | 31,378.10 | 17.55 | 3,366 | -0.50 | 47.15 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
-6.83 %
Net Income Growth
3.12 %
Cash Flow Change
169.22 %
ROE
-4.01 %
ROCE
-6.00 %
EBITDA Margin (Avg.)
11.75 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 1,002 | 1,102 | 1,191 | 1,389 | 1,456 | 1,577 | 1,766 | 2,208 | 2,421 | 2,432 | 2,575 |
| Fixed Assets | 449 | 493 | 581 | 602 | 625 | 644 | 665 | 690 | 676 | 811 | 1,196 |
| Current Assets | 526 | 565 | 571 | 737 | 784 | 900 | 1,057 | 1,393 | 1,492 | 1,321 | 1,338 |
| Capital Work in Progress | 16 | 34 | 14 | 28 | 33 | 12 | 19 | 77 | 210 | 261 | 330 |
| Investments | 0 | 0 | 12 | 11 | 12 | 13 | 17 | 20 | 19 | 20 | 473 |
| Other Assets | 537 | 575 | 584 | 748 | 785 | 907 | 1,064 | 1,422 | 1,516 | 1,340 | 0 |
| Total Liabilities | 1,002 | 1,102 | 1,191 | 1,389 | 1,456 | 1,577 | 1,766 | 2,208 | 2,421 | 2,432 | 2,575 |
| Current Liabilities | 483 | 501 | 494 | 622 | 591 | 623 | 595 | 940 | 950 | 796 | 837 |
| Non Current Liabilities | 211 | 244 | 297 | 312 | 321 | 301 | 257 | 232 | 279 | 355 | 368 |
| Total Equity | 308 | 357 | 400 | 455 | 543 | 653 | 913 | 1,036 | 1,193 | 1,282 | 1,369 |
| Reserve & Surplus | 284 | 333 | 376 | 432 | 520 | 629 | 820 | 944 | 1,100 | 1,190 | 1,278 |
| Share Capital | 24 | 24 | 24 | 24 | 24 | 23 | 93 | 93 | 93 | 92 | 91 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -1 | 1 | -0 | 0 | 1 | 2 | 2 | 13 | -14 | -1 |
| Investing Activities | -107 | -99 | -107 | -74 | -62 | -33 | -72 | -150 | -164 | -224 |
| Operating Activities | 105 | 133 | 175 | 70 | 143 | 251 | 155 | 70 | 133 | 359 |
| Financing Activities | 2 | -33 | -68 | 4 | -80 | -215 | -81 | 92 | 17 | -136 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 60.20 % | 60.14 % | 60.12 % | 59.99 % | 59.83 % | 59.98 % | 59.77 % | 59.66 % | 59.58 % | 58.70 % | 58.56 % | 57.47 % | 57.13 % | 55.67 % | 55.64 % | 55.38 % | 55.48 % | 55.22 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 2.33 % | 2.10 % | 2.56 % | 2.96 % | 2.50 % | 2.28 % | 2.25 % | 2.26 % |
| DIIs | 1.59 % | 1.97 % | 2.09 % | 2.28 % | 2.69 % | 2.76 % | 3.16 % | 3.90 % | 4.09 % | 4.71 % | 5.32 % | 5.26 % | 5.99 % | 7.35 % | 7.84 % | 8.77 % | 9.70 % | 9.94 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 31.86 % | 32.32 % | 32.68 % | 32.85 % | 32.02 % | 32.16 % | 26.66 % | 25.98 % | 25.72 % | 25.34 % | 24.65 % | 25.84 % | 25.11 % | 24.75 % | 24.80 % | 24.32 % | 23.51 % | 23.69 % |
| Others | 6.36 % | 5.57 % | 5.11 % | 4.89 % | 5.46 % | 5.10 % | 10.41 % | 10.46 % | 10.61 % | 11.25 % | 9.14 % | 9.33 % | 9.20 % | 9.27 % | 9.21 % | 9.24 % | 9.06 % | 8.89 % |
| No of Share Holders | 1,73,704 | 1,77,992 | 1,83,344 | 1,95,469 | 1,89,607 | 1,86,674 | 1,80,303 | 1,73,283 | 1,69,090 | 1,62,409 | 1,67,446 | 1,70,414 | 1,57,547 | 1,50,218 | 1,90,281 | 1,76,006 | 1,69,761 | 1,60,260 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 1 | 1 | 1 | 2 | 2.5 | 1 | 1 | 1 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.79 | 0.63 | 0.8 | 0.29 | 0.58 | 0.3 | 0.23 | 0.29 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 18 Jul 2025 |  Quarterly Result Announcement | NA | 18 Jul 2025 | 480.75 | 515.75 |
| 06 May 2025 | Quarterly Result Announcement | NA | 06 May 2025 | 351.65 | 355.05 |
| 04 Feb 2025 |  Dividend | ₹ 1.00 /share | 04 Feb 2025 | 390.15 | 423.40 |
| 29 Jan 2025 | Quarterly Result Announcement | NA | 29 Jan 2025 | 424.35 | 390.15 |
| 24 Oct 2024 | Quarterly Result Announcement | NA | 24 Oct 2024 | 504.35 | 488.25 |
| 20 Sept 2024 |  Annual General Meeting | NA | 20 Sept 2024 | 582.80 | 518.60 |
| 06 Feb 2024 | Dividend | ₹ 1.00 /share | 06 Feb 2024 | 535.45 | 519.95 |
| 08 Feb 2023 | Dividend | ₹ 1.00 /share | 08 Feb 2023 | 406.10 | 393.45 |
| 10 Feb 2022 | Dividend | ₹ 1.00 /share | 09 Feb 2022 | 497.60 | 525.00 |
| 01 Oct 2020 |  Bonus | 3:1 | 30 Sept 2020 | 741.84 | 771.30 |
Announcements
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
10 days agoAppointment Of Secretarial Auditor10 days ago
10 days agoBoard Meeting Outcome for Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025 And Outcome Of The Meeting Of The Board Of Directors Held On July 18 202510 days ago
10 days agoFinancial Results For The Quarter Ended June 30 202510 days ago
10 days agoReply To The Clarification Sought With Respect To Increase In The Volume Of Security Across The ExchangeJul 16, 2025
Jul 16, 2025Clarification sought from Aarti Drugs LtdJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 15, 2025
Jul 15, 2025Board Meeting Intimation for Audited Financial Results For The Quarter Ended June 30 2025.Jul 15, 2025
Jul 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 12, 2025
Jul 12, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 14, 2025
Jun 14, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 08, 2025
May 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 07, 2025
May 07, 2025Disclosure Under Regulation 30 - Ad-Interim Order By The CourtMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 06, 2025
May 06, 2025Board Meeting Outcome for Financial Results For The Quarter And Year Ended March 31 2025 And Appointment Of Cost AuditorMay 06, 2025
May 06, 2025Outcome Of The Board Meeting And Financial Results For The Quarter And Year Ended March 31 2025May 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 29, 2025
Apr 29, 2025Board Meeting Intimation for Audited Financial Results For The Quarter And Year Ended March 31 2025Apr 29, 2025
Apr 29, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2025
Apr 08, 2025Disclosure Under Regulation 30 Of SEBI Listing RegulationsApr 02, 2025
Apr 02, 2025Closure of Trading WindowMar 29, 2025
Mar 29, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 26, 2025
Mar 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 17, 2025
Mar 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2025
Mar 11, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations")Mar 07, 2025
Mar 07, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations") - Action Taken Or Order PassedMar 06, 2025
Mar 06, 2025Announcement Under Regulation 30 Of Listing Regulations - ESG RatingMar 03, 2025
Mar 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 28, 2025
Feb 28, 2025Disclosure Under Reg 30 Of Listing Regulations - Update On Lifting Of Import Alert 66-40 By US DFAFeb 14, 2025
Feb 14, 2025Disclosure Under Regulation 30 Of Listing Reguations- Order Of CGST And C.Ex. AuthorityFeb 07, 2025
Feb 07, 2025Disclosure Under Regulation 30 Of Listing Regulations-Feb 05, 2025
Feb 05, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-AcquisitionFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-AcquisitionFeb 03, 2025
Feb 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 31, 2025
Jan 31, 2025Announcement under Regulation 30 (LODR)-Credit RatingJan 31, 2025
Jan 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJan 29, 2025
Jan 29, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 29, 2025
Jan 29, 2025Announcement under Regulation 30 (LODR)-AcquisitionJan 29, 2025
Jan 29, 2025Integrated Filing (Financial)Jan 29, 2025
Jan 29, 2025Technical Indicators
RSI(14)
Neutral 62.98
ATR(14)
Less Volatile 20.27
STOCH(9,6)
Neutral 69.92
STOCH RSI(14)
Neutral 60.10
MACD(12,26)
Bullish 2.52
ADX(14)
Strong Trend 43.88
UO(9)
Bearish 49.30
ROC(12)
Uptrend But Slowing Down 10.53
WillR(14)
Neutral -37.97
Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 DSP Small Cap Direct Plan-Growth | 1.71% | 15153 | -0.02% | 0.27% | |
 Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth | 0.21% | 2890 | 0.00% | 0.02% | |
 Groww Nifty Total Market Index Fund Direct - Growth | 0.01% | 22 | 0.00% | 0.00% | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.12% | 8 | 0.00% | 0.02% | |
 Angel One Nifty Total Market Index Fund Direct - Growth | 0.01% | 6 | 0.00% | 0.00% | |
| Bandhan Nifty Total Market Index Fund Direct-Growth | 0.01% | -2 | 0.00% | 0.00% | |
| DSP Healthcare Fund Direct - Growth | 1.28% | 0 | 0.00% | 0.26% | |
| DSP Value Fund Direct - Growth | 0.31% | 0 | 0.00% | 0.05% | |
 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth | 1.27% | 0 | -0.01% | 0.34% | |
 Mirae Asset Nifty Total Market Index Fund Direct-Growth | 0.01% | 0 | 0.00% | 0.00% |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
